Bio-Techne expands global GMP manufacturing network
Bio-Techne has opened a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom.
The purpose-built 10,000-square-foot Bristol facility features five ISO-8 multifunctional cleanrooms and two ISO-7 cleanrooms dedicated to GMP small molecule manufacturing and product handling. Designed to meet the rigorous standards required for advanced cell therapy manufacturing, the company says the facility enhances itsability to provide customers with high-quality GMP materials supported by robust quality systems and reliable global supply.
“As the cell therapy field continues to mature, success increasingly depends on the ability to manufacture therapies consistently and at scale,” said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. “Our investment in Bristol demonstrates Bio-Techne’s commitment to providing customers with the GMP materials, manufacturing expertise, and supply chain reliability needed to accelerate development and ultimately bring transformative therapies to patients worldwide.”
Broader growth strategy
The Bristol expansion is the latest milestone in Bio-Techne’s broader strategy to build a comprehensive manufacturing network supporting every stage of the cell therapy workflow. Together with the company’s recombinant protein manufacturing operations in Minneapolis, Minnesota, its GMP capabilities in St Paul, and its strategic relationship with Wilson Wolf Corporation, a manufacturer of cell culture devices, Bio-Techne offers an increasingly integrated portfolio of GMP proteins, GMP small molecules, GMP cell media, custom manufacturing services, analytical solutions, and process development support.
“The opening of our Bristol facility represents more than additional manufacturing capacity,” said Will Geist, President of Bio-Techne’s Protein Sciences Segment. “It strengthens Bio-Techne’s ability to serve as a long-term partner for cell therapy innovators by providing the quality, scale, and global support necessary to navigate the journey from discovery to commercial supply.”
